Related by context. Frequent words. (Click for all words.) 55 LibiGel Phase III 54 Confirmatory 54 municipal recalibration 54 SUCCEED trial 53 RiVax 53 Initiated Phase 52 toxicological studies 52 Biologic License Application BLA 52 phase Ib 52 Baccalaureate BS 52 tolevamer 52 phase IIb clinical 52 IND submission 52 PROPEL trial 52 bioequivalency 52 TranSwitch Shelton CT 52 candidate brentuximab vedotin 51 nonclinical studies 51 Phase Ib clinical trials 51 Accessed #/#/# [001] 51 GSK# [002] 51 preclinical efficacy 51 BrachySil 51 subsidiary Mylan Pharmaceuticals 51 Initiate Phase 51 Fast Track Status 51 carcinogenicity studies 51 Phase Ib study 51 ALS Chemex analytical 51 opioid induced bowel dysfunction 51 preclinical toxicology 50 NEO3 50 SILENOR TM 50 Phase Ib II 50 BLA submission 50 Activities NI #-# 50 Prodarsan ® 50 phase IIa 50 MEND CABG II 50 AVADO 50 Phase Ia 50 HGS ETR2 50 bioequivalence studies 50 Phase IIb clinical trials 50 thorough QT 50 ongoing Phase 1b 50 PSMA ADC 50 timelines communicated 49 bovine thrombin 49 carcinogenicity study 49 SILENOR ™ 49 BioSante licensees 49 Abcourt Barvue project 49 Phase Ib IIa 49 dose escalation clinical 49 Panzem R NCD 49 overactive bladder AA# 49 Scobee kicked 49 Premarket Approval PMA 49 PMA submission 48 HCV SPRINT 48 IND Investigational New 48 Phase 2b clinical trials 48 Landis urine sample 48 With parimutuel betting 48 MKC# MT 48 Anthim 48 Glybera R 48 Pharmacodynamic 48 GRNVAC1 48 Omigard 48 pharmacodynamic properties 48 confirmatory Phase 3 48 mutagenicity 48 BrachySil TM 48 Investigational Device Exemption 48 pharmacokinetic studies 48 Oncotype DX colon cancer 48 supplemental biologics 48 markets therapeutic ultrasonic 48 phase 2a 48 reapproval 47 mineralogical studies 47 Dose escalation 47 multicenter Phase 47 Phase 2a clinical 47 Phase IIa trials 47 secondary efficacy endpoint 47 optical biosensors 47 GLPG# 47 Marina Genova Aeroporto complex 47 Secondary endpoints include 47 Patient Registries 47 INTERCEPT red 47 Entereg R 47 Phase Ib clinical 47 lorcaserin NDA 47 Group B CALGB 47 DXL# 47 neratinib 47 Phase III placebo controlled